A Training Set for the HRD Model in EOC

Lei Li

Status: Unknown

Conditions: Epithelial Ovarian Cancer; Loss of Heterozygosity; BRCA Mutation; Platinum Resistance; Homologous Recombination Deficiency; Prognosis

Treatments: Genetic: Homologous recombination deficiency model

Study type: Observational

Funder types: Other

Identifiers

NCT04651933

EOC-LOH

Details and patient eligibility

About

A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic testing in these patients. The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

Enrollment: 200 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 years or older
• Pathological confirmation of epithelial ovarian cancer
• With available tumor tissues
• Given consents to participate the study

Exclusion criteria

• Not meeting all of the inclusion criteria

Trial design

200 participants in 2 patient groups

Epithelial ovarian cancer patients sensitive to platinum based chemotherapy

Treatment:

Genetic: Homologous recombination deficiency model

Epithelial ovarian cancer patients resistant to platinum based chemotherapy

Treatment:

Genetic: Homologous recombination deficiency model